Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma
Open Access
- 22 October 2003
- Vol. 98 (9) , 1842-1848
- https://doi.org/10.1002/cncr.11754
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780Journal of Clinical Oncology, 2001
- Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate CancerJournal of Clinical Oncology, 2001
- Clinical states in prostate cancer: toward a dynamic model of disease progressionUrology, 2000
- Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 1999
- Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinomaAnnals of Oncology, 1999
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivoThe Prostate, 1992
- Plasma Concentrations of Estramustine Phosphate and Its Major Metabolites in Patients with Prostatic Carcinoma Treated with Different Doses of Estramustine Phosphate (Estracyt®).Scandinavian Journal of Urology and Nephrology, 1981
- Studies on Phenolic Steroids in Human Subjects. XIV. Fate of a Nitrogen Mustard of Estradiol-17βJournal of Clinical Endocrinology & Metabolism, 1975